VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTH

VERTEX (VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTH

(1/9)
Good evening, Tradingview! Vertex (VRTX) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀

(2/9) – REVENUE RUSH

• Q4 Haul: $ 2.91B—16% jump from last year 💥
• Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊
• ‘25 Outlook: $11.75-$ 12B—6-9% growth
CF keeps humming—newbies add zest!

(3/9) – BIG WINS

• Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍
• Alyftrek: CF drug for 6+—ships now 🚗
• Cash: $11.2B—loaded for action 🌟
VRTX storms pain—CF stays golden!

(4/9) – SECTOR CHECK

• Valuation: 11x sales—above 9x avg 📈
• Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium?
• Growth: 12% beats biotech’s 5-7% 🌍
VRTX flexes—value or stretch?

(5/9) – RISKS ON TAP

• Payers: Journavx needs coverage—hiccups? ⚠️
• Trikafta: 93% of sales—big lean 🏛️
• Comp: Pain rivals, CF safe—for now 📉
Hot streak—can it dodge the bumps?

(6/9) – SWOT: STRENGTHS

• CF King: Trikafta, Alyftrek lock it in 🌟
• Pain Play: Journavx eyes $ 4B peak 🔍
• Cash: $11.2B—war chest ready 🚦
VRTX’s got muscle and moolah!

(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES

• Weaknesses: Trikafta reliance—eggs in one basket 💸
• Opportunities: Casgevy rolls, pain grows 🌍
Can VRTX zap past the risks?

(8/9) – VRTX’s Q4 surge—what’s your vibe?

1️⃣ Bullish—Pain pays off big.
2️⃣ Neutral—Solid, but risks linger.
3️⃣ Bearish—Growth hits a wall.

Vote below! 🗳️👇

(9/9) – FINAL TAKEAWAY

VRTX’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?